Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep;32(9):1519-1522.
doi: 10.1038/s41433-018-0132-1. Epub 2018 May 30.

Clinical experience on diagnosis and treatment for malignancy originating from the dacryocyst

Li-Juan Zhu  1 , Yu Zhu  2 , Shang-Chen Hao  1 , Pei Huang  1 , Lin-Lin Wang  1 , Xiu-Hong Li  1 , Li-Hong Lian  1 , Ke Zhang  1
Affiliations

Clinical experience on diagnosis and treatment for malignancy originating from the dacryocyst

Li-Juan Zhu et al. Eye (Lond). 2018 Sep.

Abstract

Objective: To summarize clinical experience on the diagnosis and treatment for malignancy originating from the dacryocyst.

Methods: We retrospectively analyzed clinicopathological data from 12 cases that were diagnosed with malignancy originating from the dacryocyst by histopathological examination in our hospital from 2007 to 2017.

Results: Of the 12 cases with malignancy originating from the dacryocyst, 7 were male and 5 were female, with a mean age of 53 years (range, 4-81). Clinical manifestations included a mass in the dacryocyst area in 12 cases, epiphora in 9 cases, pyoid tears in 2 cases, bloody tears in 3 cases, and redness and swelling in the dacryocyst area in 2 cases. Lymphoma occurred in six cases, malignant melanoma in three cases, embryonal rhabdomyosarcoma in one case, and squamous cell carcinoma in two cases.

Conclusions: Misdiagnosis and missed diagnosis readily occur for malignancy originating from the dacryocyst because its clinical manifestations are diverse. For the suspected patients, it is necessary to perform related examinations. Individualized treatment should be adopted based on pathological types and specific conditions.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. Krishna Y, Coupland SE. Lacrimal sac tumors--a review. J Asia Pac Ophthalmol. 2017;6:173–8. doi: 10.22608/APO.201713. - DOI - PubMed
    1. Heindl LM, Jünemann AG, Kruse FE, Holbach LM. Tumors of the lacrimal drainage system. Orbit. 2010;29:298–306. doi: 10.3109/01676830.2010.492887. - DOI - PubMed
    1. Montalban A, Liétin B, Louvrier C, Russier M, Kemeny JL, Mom T, et al. Malignant lacrimal sac tumors. Eur Ann Otorhinolaryngol Head Neck Dis. 2010;127:165–72. doi: 10.1016/j.anorl.2010.09.001. - DOI - PubMed
    1. Stephanyszyn MA, Hidayat AA, Pe’er JJ, Flanagan JC. Lacrimal sac tumors. Ophthal Plast Reconstr Surg. 1994;10:169–84. doi: 10.1097/00002341-199409000-00005. - DOI - PubMed
    1. Ni C, D’Amico DJ, Fan CQ, Kuo PK. tumors of the lacrimal sac: a clinicopathologicalanalysis of 82 cases. Int Opthalmol Clin. 1982;22:121–40. doi: 10.1097/00004397-198202210-00010. - DOI - PubMed

MeSH terms